# Plasma Cell Neoplasms

## Overview

Plasma cell neoplasms are clonal proliferations of immunoglobulin-secreting, terminally differentiated B-cells. The clinical spectrum ranges from the premalignant monoclonal gammopathy of undetermined significance (MGUS) through smoldering myeloma to active multiple myeloma and plasma cell leukemia. AL amyloidosis represents a distinct manifestation in which misfolded immunoglobulin light chains deposit systemically as pathologic fibrils.

## Monoclonal Gammopathy of Undetermined Significance (MGUS)

### Diagnostic Criteria

MGUS is defined by a serum monoclonal protein (M-protein) below 3 g/dL, bone marrow plasma cells below 10 percent, and the absence of end-organ damage as defined by the CRAB criteria (calcium elevation, renal insufficiency, anemia, and bone lesions) or any myeloma-defining events.

### Epidemiology and Risk

MGUS is present in approximately 3 to 4 percent of the population over age 50, with prevalence increasing with age. The rate of progression to myeloma or a related malignancy is roughly 1 percent per year, and this risk never disappears regardless of the duration of stable disease. Risk stratification incorporates the M-protein level, non-IgG isotype, and an abnormal free light chain ratio.

### Subtypes

Non-IgM MGUS (IgG, IgA, or IgD) carries a risk of progression to multiple myeloma. IgM MGUS may progress to Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) or other lymphoproliferative disorders rather than typical myeloma. Light chain MGUS is defined by an abnormal free light chain ratio without a detectable heavy chain M-protein and carries risk of progression to light chain myeloma or AL amyloidosis.

## Smoldering Multiple Myeloma (SMM)

### Diagnostic Criteria

Smoldering myeloma is defined by a serum M-protein of 3 g/dL or greater and/or bone marrow plasma cells between 10 and 59 percent, in the absence of CRAB criteria or myeloma-defining events. The risk of progression is substantially higher than MGUS, approximately 10 percent per year during the first 5 years.

### Risk Stratification (2/20/20 Model)

The 2/20/20 model stratifies smoldering myeloma based on three factors: serum M-protein of 2 g/dL or greater, free light chain ratio of 20 or greater, and bone marrow plasma cells of 20 percent or greater. Patients with zero risk factors are low risk (approximately 5 percent per year progression), those with one risk factor are intermediate risk (approximately 10 percent per year), and those with two or three risk factors are high risk (approximately 20 percent per year).

## Multiple Myeloma (MM)

### Diagnostic Criteria (IMWG 2014 Updated)

The diagnosis requires clonal bone marrow plasma cells of 10 percent or greater, or a biopsy-proven plasmacytoma, plus one or more myeloma-defining events. These events include the CRAB criteria (calcium above 11 mg/dL, creatinine above 2 mg/dL or creatinine clearance below 40, hemoglobin below 10 g/dL or more than 2 below normal, and lytic bone lesions or pathologic fractures) and the newer SLiM biomarkers of malignancy: 60 percent or more marrow plasma cells, an involved/uninvolved free light chain ratio of 100 or greater, or more than one focal lesion of 5 mm or larger on MRI.

### Bone Marrow Morphology

Plasma cells may appear mature, with the classic eccentric nucleus, perinuclear hof (pale Golgi zone), and clockface chromatin, or they may be immature with plasmablastic features including visible nucleoli and reduced chromatin condensation. The infiltration pattern may be interstitial, nodular, or diffuse. Mature morphology confers a better prognosis while immature or plasmablastic morphology is adverse. Dutcher bodies (intranuclear PAS-positive inclusions) and Russell bodies (cytoplasmic immunoglobulin inclusions) may be present. Flame cells with bright eosinophilic cytoplasm are characteristic of IgA myeloma.

### Immunophenotype

CD138 (syndecan-1) is the best immunohistochemical marker for identifying plasma cells on biopsy sections. CD38 (bright) is the primary marker used in flow cytometry. Aberrant markers that distinguish neoplastic from normal plasma cells include CD56 positivity (normal plasma cells are CD56-negative), CD117 positivity, CD19 negativity (normal plasma cells are CD19-positive), and usually CD20 negativity. Light chain restriction (kappa or lambda) by IHC or in situ hybridization confirms clonality. Loss of CD56 is observed in plasma cell leukemia.

### Laboratory Workup

#### Serum Protein Electrophoresis (SPEP)

SPEP detects the M-spike in the gamma region (or as beta-gamma bridging in IgA myeloma) and quantifies the M-protein concentration. However, a normal SPEP does not exclude myeloma, since light chain-only and non-secretory myeloma will not produce a detectable M-spike.

#### Immunofixation Electrophoresis (IFE)

IFE identifies the heavy chain class (IgG, IgA, IgD, or IgM) and light chain type (kappa or lambda) of the monoclonal protein. It is more sensitive than SPEP and can detect small M-proteins that fall below the SPEP detection threshold.

#### Serum Free Light Chains (sFLC)

This assay measures kappa and lambda free light chains and their ratio. It is essential for evaluating light chain myeloma, non-secretory myeloma, and AL amyloidosis. The normal ratio ranges from 0.26 to 1.65, and an involved/uninvolved ratio of 100 or greater constitutes a myeloma-defining event.

#### Urine Studies

A 24-hour urine protein electrophoresis (UPEP) and immunofixation detect Bence Jones protein, which represents monoclonal light chains filtered by the kidneys.

### Cytogenetics and FISH Risk Stratification

#### Standard Risk

The translocation t(11;14)(q13;q32), producing a CCND1-IGH fusion, is the most common translocation in myeloma. It is associated with lymphoplasmacytic morphology and predicts sensitivity to venetoclax. Hyperdiploidy, defined by trisomies of odd-numbered chromosomes (3, 5, 7, 9, 11, 15, 19, 21), also carries standard risk.

#### High Risk

Several cytogenetic abnormalities define high-risk disease: t(4;14)(p16.3;q32) producing FGFR3-IGH/MMSET (adverse, though partially overcome by proteasome inhibitors), t(14;16)(q32;q23) involving IGH-MAF, t(14;20)(q32;q12) involving IGH-MAFB, del(17p)/TP53 deletion (associated with extramedullary disease), and gain of 1q21 (adverse when four or more copies are present, termed amp1q). Patients with two or more high-risk features are classified as "double-hit" and carry a very adverse prognosis.

#### FISH Panel (Minimum Required)

The minimum FISH panel should include t(4;14), t(14;16), t(11;14), del(17p), gain(1q21), and assessment for hyperdiploidy. Crucially, FISH must be performed on CD138-selected (enriched) plasma cells to obtain accurate results.

### Revised International Staging System (R-ISS)

| Stage | Criteria | Median OS |
|-------|----------|-----------|
| I | ISS I (B2M <3.5, albumin >=3.5) + standard-risk cytogenetics + normal LDH | ~80 months |
| II | Not I or III | ~50 months |
| III | ISS III (B2M >=5.5) + high-risk cytogenetics and/or elevated LDH | ~25 months |

## Special Variants

### Plasma Cell Leukemia

Plasma cell leukemia is defined by 2 x 10^9/L or more circulating plasma cells or plasma cells constituting 20 percent or more of the WBC differential. It may arise de novo (primary) or through transformation from existing myeloma (secondary). It is characterized by CD56 negativity and frequent TP53 abnormalities, and it carries the worst prognosis among plasma cell neoplasms.

### Solitary Plasmacytoma

A solitary plasmacytoma is a single mass of clonal plasma cells without evidence of systemic disease. It may be osseous (arising in bone) or extraosseous (arising in soft tissue). Diagnostic criteria require a single lesion with no or only a small M-protein, a normal bone marrow, and no CRAB features. Treatment is radiation therapy, though 40 to 70 percent of patients eventually progress to multiple myeloma.

### Waldenstrom Macroglobulinemia / Lymphoplasmacytic Lymphoma (LPL)

This entity is an IgM-secreting neoplasm with lymphoplasmacytic morphology in the bone marrow. The MYD88 L265P mutation is present in more than 90 percent of cases and serves as a near-defining molecular feature. CXCR4 mutations occur in approximately 30 percent and are associated with resistance to ibrutinib. Hyperviscosity syndrome results from elevated IgM levels, manifesting as visual changes, headache, and bleeding. The key differential is marginal zone lymphoma with plasmacytic differentiation, and MYD88 L265P positivity strongly favors LPL.

## AL Amyloidosis

### Pathogenesis

In AL amyloidosis, misfolded monoclonal immunoglobulin light chains (usually lambda) deposit in tissues as beta-pleated sheet fibrils. The underlying clonal plasma cell disorder may range from MGUS through smoldering myeloma to overt myeloma in a minority of cases.

### Diagnosis

The gold standard histochemical stain is Congo red, which produces characteristic apple-green birefringence under polarized light. An abdominal fat pad aspirate offers a sensitivity of approximately 70 to 80 percent as a screening procedure. Bone marrow biopsy with Congo red staining provides both tissue confirmation and plasma cell quantification. Direct organ biopsy (heart, kidney, nerve, or liver) offers definitive tissue confirmation. Mass spectrometry-based amyloid typing on formalin-fixed paraffin-embedded tissue is the gold standard for subtyping (distinguishing AL from AA, ATTR, and other rare subtypes).

### Organ Involvement

Amyloid deposits affect the heart (causing restrictive cardiomyopathy), kidneys (causing nephrotic syndrome), liver (causing hepatomegaly), nerves (causing peripheral neuropathy), GI tract, and soft tissues (causing macroglossia and periorbital purpura). Cardiac involvement is the major determinant of prognosis, and cardiac biomarkers (NT-proBNP and troponin) are used for staging.

<image>A medical illustration showing the spectrum of plasma cell morphology on bone marrow aspirate smears (Wright-Giemsa stain). Panel A: Normal mature plasma cells with eccentric nucleus, clockface chromatin, perinuclear hof (pale Golgi zone), and basophilic cytoplasm. Panel B: Myeloma with mature morphology showing sheets of plasma cells with preserved cytoplasmic features and occasional binucleation. Panel C: Myeloma with immature/plasmablastic morphology showing large cells with prominent central nucleoli, open chromatin, high N:C ratio, and reduced perinuclear hof. Panel D: Flame cells (IgA myeloma) with bright eosinophilic cytoplasm. Panel E: Dutcher bodies (intranuclear PAS-positive inclusions, arrow) and Russell bodies (large eosinophilic cytoplasmic inclusions). Panel F: CD138 IHC on core biopsy highlighting extensive interstitial and nodular plasma cell infiltration.</image>

<image>A medical illustration demonstrating amyloid diagnosis. Panel A: Congo red stain on a tissue section showing amorphous pink/salmon-colored amyloid deposits in vessel walls and interstitium. Panel B: The same section under polarized light showing characteristic apple-green birefringence of amyloid fibrils. Panel C: Abdominal fat pad aspirate with Congo red staining showing amyloid deposits between adipocytes. Panel D: A schematic diagram showing the workup algorithm for amyloid typing: tissue biopsy with Congo red positivity leading to mass spectrometry-based proteomic analysis for definitive subtyping (AL kappa, AL lambda, AA, ATTR wild-type, ATTR hereditary, and other rare subtypes).</image>

## Clinical Pearls

FISH on plasma cells must be performed on CD138-selected (enriched) samples because testing unselected marrow dilutes the abnormal clone and may yield false-negative results. The translocation t(11;14) in myeloma is associated with lymphoplasmacytic morphology and predicts sensitivity to venetoclax, making it an important translocation to identify in every new myeloma patient. A normal SPEP does not exclude myeloma; serum free light chains must always be checked since light chain myeloma produces no intact immunoglobulin, and non-secretory myeloma should also be considered.

The MYD88 L265P mutation is present in more than 90 percent of lymphoplasmacytic lymphoma/Waldenstrom cases but is rare in marginal zone lymphoma with plasmacytic differentiation, making it the best single discriminator between these two entities. AL amyloidosis must be subtyped by mass spectrometry rather than immunohistochemistry alone, as IHC is unreliable for amyloid typing and misclassification can lead to inappropriate treatment. The distinction between MGUS and smoldering myeloma rests on M-protein level and marrow plasma cell percentage; both lack end-organ damage but differ substantially in progression risk. Finally, plasmablastic morphology in myeloma confers adverse prognosis and may overlap morphologically with plasmablastic lymphoma, which is EBV-associated and arises in immunosuppressed patients.

## References
- Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*. 2014;15(12):e538-e548.
- Palumbo A, et al. Revised International Staging System for Multiple Myeloma. *J Clin Oncol*. 2015;33(26):2863-2869.
- Kyle RA, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2002;346(8):564-569.
- Treon SP, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. *N Engl J Med*. 2012;367(9):826-833.
- Vrana JA, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. *Blood*. 2009;114(24):4957-4959.